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While guidelines recommend empirical cefepime therapy in febrile neutropenia, the mortality benefit of cefepime has been con-
troversial. In light of this, recent reports on pharmacokinetic changes for several antibiotics in febrile neutropenia and the con-
sequent suboptimal exposure call for a pharmacokinetic/pharmacodynamic evaluation of current dosing. This study aimed to
assess pharmacokinetic/pharmacodynamic target attainment from a 2-g intravenous (i.v.) every 8 h (q8h) cefepime regimen in
febrile neutropenic patients with hematological malignancies. Cefepime plasma concentrations were measured in the 3rd, 6th,
and 9th dosing intervals at 60% of the interval and/or trough point. The selected pharmacokinetic/pharmacodynamic targets
were the proportion of the dosing interval (60% and 100%) for which the free drug concentration remains above theMIC
(fT>MIC). Target attainment was assessed in reference to theMIC of isolated organisms if available or empirical breakpoints if
not. The percentage of fT>MIC was also estimated by log-linear regression analysis. All patients achieved>60% fT>MIC in the 3rd
and 6th dosing intervals. A 100% fT>MIC was not attained in 6/12, 4/10, and 4/9 patients in the 3rd, 6th, and 9th dose intervals,
respectively, or in 14/31 (45%) of the dosing intervals investigated. On the other hand, 29/31 (94%) of trough concentrations
were at or above 4 mg/liter. In conclusion, for patients with normal renal function, a high-dose 2-g i.v. q8h cefepime regimen
appears to provide appropriate exposure if the MIC of the organism is<4 mg/liter but may fail to cover less susceptible
organisms.
The introduction of cefepime into clinical practice was widelyaccepted due to its broad-spectrum activity. Cefepime is active
against such organisms as Acinetobacter baumannii, Pseudomonas
aeruginosa, and Enterobacteriaceae with relatively lowMICs com-
pared to those of other broad-spectrum -lactam antibiotics (1,
2). Therefore, it is considered a good choice for the empirical
management of febrile neutropenia, either as a monotherapy
agent or as part of combination regimens (3, 4).
While several comparative outcome trials suggest cefepime is
clinically as effective as other -lactam antibiotics, meta-analyses
(5, 6) of data from these trials report an increased risk ofmortality
associated with cefepime therapy, which was particularly high in
febrile neutropenic patients (7). Conversely, a later meta-analysis
by the U.S. Food and Drug Administration (FDA), which in-
cluded several additional unpublished trials, concluded that there
is no such association (8, 9). In addition, specific analysis of trials
of febrile neutropenic patients did not show any statistically sig-
nificant increase in mortality (9). The controversy continues as
the methodological issues of the FDA’s and previous meta-analy-
ses are challenged and debated (7, 10–12). However, there is little
biological plausibility for the claimed risk of mortality, which was
originally suggested to be related to unrecognized toxicity or poor
in vivo antibiotic efficacy (6). Suboptimal antibiotic concentration
and possible pharmacokinetic/pharmacodynamic (PK/PD) ex-
planations were implicated.
PK/PD describes the relationship between the dose of antibi-
otics, the resulting concentrations achieved in biological fluids,
such as plasma or interstitial fluid, and the associated antibacterial
activity. Characteristic relationships exist between plasma con-
centrations and antibacterial activity. For -lactam antibiotics,
including cefepime, the duration of the dosing interval for which
the free drug concentration remains above the MIC (fTMIC), is
the PK/PD index that guides dose selection and objectively mea-
sures dosing adequacy (13). For cefepime and other cephalospo-
rins that exhibit the least postantibiotic effect among the -lac-
tams, 60 to 70% fTMIC is the conventional conservative PK/PD
target (13), even though 100% fTMIC may be required in immu-
nocompromised hosts (14).
Any changes in the PK or PD properties of antibiotics demand
adjustment of the dosing regimen to ensure attainment of the
required PK/PD target (15). The PK of antibiotics is amenable to
pathophysiology-driven alterations in some special patient popu-
lations with marked infections or inflammation, including those
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with neutropenic fever and malignancy. PK changes are observed
as increases in the volume of distribution and/or clearance and
subsequent low plasma and tissue concentrations. The PD re-
sponse may be affected due to changes in bacterial susceptibility.
Such PK/PD changes in febrile neutropenic patients are docu-
mented for-lactam antibiotics (16), although there is a dearth of
information on cefepime. Navas et al. (17) have reported inade-
quate exposure from a traditional cefepime regimen (2 g intrave-
nous [i.v.] every 12 h [q12h]) in febrile neutropenic patients.
However, a higher dosing regimen (2 g i.v. every 8 h [q8h]) is now
more commonly used in neutropenic patients with normal renal
function. The objective of this work was therefore to assess PK/PD
target attainment from an intermittent 2-g i.v. q8h cefepime dos-
ing regimen in febrile neutropenic patients with hematological
malignancies.
MATERIALS AND METHODS
Study setting, patients, and drug administration. The study was con-
ducted at The Queen Elizabeth Hospital (TQEH), Adelaide, South Aus-
tralia. TQEH is an acute care teaching hospital providing emergency, in-
patient (311 beds), outpatient, andmental health services for a population
of over a quarter of a million. Patients aged18 years were preconsented
while receiving chemotherapy and/or stem cell transplant at the hematol-
ogy unit of TQEH for the management of hematological malignancies.
Thereafter, patients were enrolled when they developed febrile neutrope-
nia, which was defined as the presence of a single oral temperature of
38.3°C (101°F) or a temperature of38.0°C (100.4°F) for1 h or with
a neutrophil count of 500 cells/mm3 or a count of 1,000 cells/mm3
with a predicted decrease to 500 cells/mm3 (18). Additional inclusion
criteria were prescription of cefepime for the management of febrile neu-
tropenia and the presence of a peripherally inserted central catheter
(PICC) for blood sampling. Patients were excluded if they had a known or
suspected allergy to cefepime, did not have a PICC line, or were pregnant.
The study was conducted in accordance with an Australian national state-
ment on ethical conduct in human research as well as the Declaration of
Helsinki. Ethics approval was granted by the Human Research Ethics
Committees of TQEH (HREC/13/TQEHLMH/301) and the University of
South Australia (application ID 0000032581).
All patients received 2 g cefepime administered every 8 h via intermit-
tent i.v. infusion over 30 min, followed by 15 min of line flushing. In
addition, all patients received gentamicin (7 mg/kg of body weight once
daily) for 1 to 3 days.
Data collection and blood sampling.Data describing patient charac-
teristics were collected from electronic or paper-based medical records
and included the following: demographic characteristics, diagnosis ofma-
lignancies and infections, microbiological data, vital signs, and clinical
hematological and chemistry data. Five blood samples were taken per
patient over 3 days to monitor assumed steady-state cefepime concen-
trations. The first two samples were taken after the third dose: one at
60% of the dosing interval and the other as a trough 15 min before the
next dose. The next two samples were taken similarly in the sixth
dosing interval, and finally, one trough sample was taken at the end of
the ninth dosing interval.
Drug assay. A liquid chromatography-tandem mass spectrometry
(LC-MS/MS) method previously validated for simultaneous analysis of
-lactam antibiotics (19) was extended to include cefepime on an ultrap-
erformance liquid chromatography system (Shimadzu Corp., Kyoto, Ja-
pan) connected to an API3200 mass detector (AB Sciex Pte., Ltd.). The
sample preparation procedures and mobile phase systems were as for-
merly described. Chromatographic separation was achieved on a C18 col-
umn (Zorbax Eclipse XDB-C18, 2.1 mm by 150 mm, 3.5 m; Agilent
Technologies, Inc.) via gradient elution. Multiple reactions monitoring
(MRM) was performed in a positive mode using electrospray ionization.
The masses of precursor and product ions monitored for cefepime were
481.1 and 125.0, respectively. Piperacillin was used as an internal standard
with MRM charge/mass ratios (m/z) of 518.16/143.10. Quadratic regres-
sion with a weighting scheme of 1/(x  x) best described the data for
calibration curves over the concentration range of 0.25 to 50 mg/liter
(r2 0.9). The lower limit of quantification was 0.25 mg/liter. The inter-
day and intraday mean accuracies of quality control samples (QCs)
ranged from 99% to 105% and 99% to 110%, respectively. Intraday and
interday coefficients of variation were less than 15% at all QC concentra-
tions. The mean recovery was 95%. Stability data over three freeze-thaw
cycles, for 4 h on the benchtop as well as for 12 h postpreparation, were
within the requirement guidelines (20).
Pharmacokinetic analysis. First, considering log-linear PK (21), con-
centrations at 0.75, 2, 4, and 6 h were estimated based on the two concen-
trationsmeasured in the third dosing interval. Then the resulting concen-
tration-time profiles, including the measured concentrations, were used
to perform noncompartmental PK analysis using an MS Excel add-in
program, PK Solver (22). The value 0.5 h was entered for the (bolus)
infusion time, and the linear trapezoidal method was selected for calcula-
tion of the area under the curve from 0 to infinity (AUC0–inf).
Statistical analysis. IBM SPSS Statistics version 19.0 (SPSS, Inc., Chi-
cago, IL) software was used to execute statistical analysis. Characteristics
of study participants were summarized using descriptive statistics. As ap-
propriate, the Mann–Whitney U test or Kruskal-Wallis test was used to
compare observed concentrations among the dosing intervals. A P value
of0.05 was considered statistically significant.
Pharmacodynamic assessment. The blood sampling times were se-
lected to enable assessment of the achievement of 60% fTMIC and 100%
fTMIC without calculating the exact duration for which the free concen-
tration remains above theMIC. Free cefepime concentrations were calcu-
lated from total plasma concentration assays considering 19% protein
binding (23, 24). When culture tests were positive, specific MICs for the
isolated organisms were used if available. When there were no organisms
identified, the highest MIC of all susceptible organisms (8 mg/liter) was
used according to the Clinical and Laboratory Standards Institute (CLSI)
and the European Committee on Antimicrobial Susceptibility Testing
(EUCAST) MIC breakpoints (25, 26). Additionally, the percentage of
fTMIC was estimated for the third and sixth dosing intervals by means of
log-linear regression analysis based on the two concentrations measured
in the terminal elimination phase.
RESULTS
Twelve patients with neutropenic fever and malignancy were en-
rolled in the study. Characteristics of these study participants are
presented in Table 1.Most patients exhibited slight hypoalbumin-
emia and did not have renal dysfunction. Blood cultures tested
positive for four patients. Two patients were obese, four patients
were overweight, and the rest had normal body weight.
Fifty-three plasma concentrations were analyzed from the 12
patients in 31 assumed steady-state dosing intervals. For two pa-
tients, only two concentrations each were measured during the
third dosing interval, and for one patient, a concentration was not
measured after the sixth dosing interval because cefepime was
discontinued by clinicians treating the patient. PK parameter es-
timates for all patients are summarized in Table 2. Figure 1 depicts
the distribution of free plasma cefepime concentrationsmeasured
at 60% of the dosing interval in the third and sixth dosing inter-
vals. All concentrations were above the highestMIC of susceptible
organisms (8 mg/liter), and hence60% fTMIC was attained in
all patients. A comparison of unbound trough cefepime concen-
trations from all participants in the third, sixth, and ninth dosing
intervals is presented in Fig. 2. No statistically significant differ-
ence in trough concentrations was noted among the three dosing
intervals (P  0.975), although the median value was relatively
Sime et al.
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higher in the sixth dosing interval. Nearly half of the unbound
trough concentrations, 14/31 (45%), were below 8 mg/liter (the
highest MIC). In contrast, 29/31 (94%) of trough concentration
were at or above 4 mg/liter. No trough concentration less than 2
mg/liter was observed. The distributions of percentages of fTMIC
estimates in the third and sixth dosing intervals are depicted in Fig.
3. Six of the 12 patients during the third interval, 4/10 patients
during the sixth interval, and 4/9 patients in the ninth interval did
not achieve 100% fTMIC. However, the percentages of fTMIC
were greater than 70% and 60% for all patients in the third and
sixth dosing intervals, respectively.
DISCUSSION
In the context of the growing evidence of altered antibiotic PK and
subsequent underexposure in febrile neutropenia, a high-dose
cefepime regimen (2 g i.v. q8h) has not been widely subjected to
PK/PD assessment. In addition to this, a clear picture is lacking
with regard to the underlying causes of the controversial claims of
increased risk of mortality associated with cefepime therapy, ex-
cept for thoughts of the potential role of toxicity as well as under-
exposure from conventional dosing (6, 27). Although this study
did not aim to describe cefepime toxicities, it evaluated PK/PD
exposure from a 2-g dose administered q8h via intermittent i.v.
infusion in febrile neutropenic patients with malignancies.
The median volume of distribution of cefepime estimated in
this study is higher than that reported for healthy individuals from
a phase I study (34 liters versus 18 liters) (21). Similarly high
mean/median volumes of distribution have been previously re-
ported for critically ill patients (27) (29 liters), burn patients
(28) (26 liters), and general ward patients with normal renal
function (29) (32 liters). The observed significant expansion in
volume of distribution may be attributable to a combination of
various factors, including capillary fluid extravasation, high-vol-
ume fluid therapy, and the markedly increased body mass index
TABLE 2 Noncompartmental pharmacokinetic parameter estimates of
cefepime from 12 febrile neutropenic patients with hematological
malignancies
Parametera Mean Median IQRb
Vss (liters/kg) 33.4 34 24.8–42.7
CL (liters/h) 8.6 8.7 6.8–10.8
t1/2 (h) 2.7 2.5 2.4–3.0
MRT (h) 3.9 3.6 3.5–4.4
AUC0–inf (mg/liter · h) 269 232 186–294
kel (1/h) 0.3 0.3 0.2–0.3
a Vss, volume of distribution at steady state; CL, total clearance; t1/2, half-life; MRT,
mean residence time; AUC0–inf, area under the concentration versus time curve from
time zero to infinity; kel, terminal elimination rate constant.
b IQR, interquartile range.
FIG 1 Box-and-whisker plot of unbound cefepime plasma concentrations at
60% of the third and sixth dosing intervals in febrile neutropenic patients with
hematological malignancy receiving 2-g i.v. q8h dosing. The whiskers extend
to 1.5 times the interquartile range fromQ1 or Q3, or the highest/lowest point
within the range. Outlier points are those that are away from the interquartile
range by greater than 1.5 times from Q1 or Q3. The black and gray areas
represent the distances from the 1st quartile to the median and from the me-
dian to the 3rd quartile, respectively.
FIG 2 Unbound cefepime plasma concentrations from trough samples in the
third, sixth, and ninth dosing intervals in patients with neutropenic fever and
hematological malignancy receiving 2-g i.v. q8h dosing.
FIG 3 Box-and-whisker plot of proportions of the dosing interval that the free
cefepime concentration remained above the MIC of 8 mg/liter in 12 febrile
neutropenic patients with hematological malignancy receiving 2-g i.v. q8h
dosing. Thewhiskers extend to 1.5 times the interquartile range fromQ1orQ3
or the highest/lowest point within the range. The black and gray areas repre-
sent the distances from the 1st quartile to the median and from the median to
the 3rd quartile, respectively.
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(BMI)/obesity observed in our cohort (Table 1) (16, 30, 31). On
the other hand, previous estimates of total clearance and half-life
in healthy volunteers (21) (8.4 liters/h for 2.3 h) and critically ill
burn patients (28) (9 liters/h for 2.45 h) are comparable with
this study (8.7 liters/h for 2.5 h). Given that cefepime is predom-
inantly eliminated unchanged via glomerular filtration (21), the
similarities to healthy individuals’ data are sensible as all patients
in this study exhibited normal renal function (Table 1). However,
augmented renal clearance is not uncommon in febrile neutro-
penic patients with normal renal function; therefore, higher than
usual clearance of cefepime is a possibility in such cases (32).
Considering the conservative PK/PD target of 60% fTMIC,
unbound cefepime concentrations were greater than the highest
anticipated MIC of susceptible organisms (8 mg/liter) for all pa-
tients in this study. The median free concentration at 60% of the
dosing interval was 17mg/liter, a value greater than 4 theMICof
cefepime for themajority of organisms, includingmany P. aerugi-
nosa clinical isolates for which cefepime MIC values may be 4
mg/liter (29). For -lactam antibiotics, including cefepime, max-
imal bacterial killing is expected to occur at concentrations of
about 4 to 5 the MIC (33). However, a more pragmatic PK/PD
target for -lactam antibiotics in immunocompromised neutro-
penic patientsmay be 100% fTMIC, which was attained in 55%of
the dosing intervals assessed in this study, when considering the
empirical MIC breakpoint of 8 mg/liter. The median unbound
trough cefepime concentrations were just below or above 8 mg/
liter for three consecutive days at steady state (Fig. 2) and were
consistent with previous findings in critically ill patients (27).
Therefore, if considering PK/PD targets, a high-dose cefepime
regimen (2 g i.v. q8h) appears to be adequate for the majority of
patients and organisms. This dose provided 100% fTMIC cover-
age for 94%of the dosing intervals in this study for organismswith
MIC breakpoints of 4 mg/liter. The high-dose regimen is also
supported by previous studies with less frequent dosing schedules
(2 g i.v. every 12 h [q12h]) that have shown that trough concen-
trations can be low for themajority of febrile neutropenic patients
(17). Similar findings in critically ill patients suggest that such low
dosing regimens are inadequate when considering empirical ther-
apy against less susceptible Gram-negative organisms (27, 34).
Median trough concentrations in this study were also marginally
close to the 8-mg/liter breakpoint (Fig. 2), suggesting that de-
escalation from the current high-dose therapy may result in sub-
optimal exposure in patients with normal renal function.
Sincemost organisms have a relatively lowMIC breakpoint for
cefepime (MIC of2), with the exception of few Gram-negative
isolates (e.g., P. aeruginosa) (25), the trough concentrations
achieved in this study (Fig. 2) will also meet a more aggressive
PK/PD target of 100% fT4 MIC for most patients. A 100%
fT
4 MIC
has been recommended for cefepime in order to max-
imize microbiological success in treatment of Gram-negative
infections (33). However, this may require high trough con-
centrations for pseudomonal infections (32mg/liter), risking
toxicity. Lamoth et al. (35) previously suggested that the
threshold for cefepime-induced neurotoxicity, including those
other than seizure, may be as low as 15 to 20 mg/liter (total
concentration), although convulsive seizures are more likely to
occur at concentrations of about 70 mg/liter or higher (36). Six
out of 31 trough concentrations in this study (19%) fall within
the 15- to 20-mg/liter range, although no neurological toxici-
ties were observed. Given high variability in concentrations
(the coefficient of variation of trough concentrations was about
50% in this study), the high-dose therapy is likely to result in
concentrations beyond these “low thresholds” even in patients
with normal renal function. Indeed there are some case reports
of neurotoxicity in patients with normal renal function (37,
38). If the aforementioned thresholds can be validated in large
trials, the range from empirical coverage to “toxicity” (trough
concentrations of 8 to 20 mg/liter) would amount to a narrow
therapeutic index warranting regular therapeutic drug moni-
toring (TDM).
The high-dose regimen (2 g i.v. q8h) was used in most of the
published comparative clinical trials with adult febrile neutro-
penic patients (about 60%) included in the meta-analyses that
initially suggested increased mortality with cefepime therapy;
while low-dose regimens (1 to 2 g twice daily) were used in the rest
(5, 6). Whereas studies that monitored cefepime concentrations
from the low-dose regimens (17, 27, 34) suggest that underexpo-
sure is likely,measured concentrations from this and other studies
(27) of the high-dose therapy indicate that this may occur only if
high-MIC organisms are involved. Given the sample size limita-
tion of this study, more data from large trials may be necessary to
exclusively rule out underexposure against usually susceptible or-
ganisms in the presence of variable and continually changing sus-
ceptibility to current antibiotics. In addition to this, for some spe-
cial population groups, such as those with high creatinine
clearance and obesity, concentrations are likely to be far below the
empirical breakpoints. The lowest unbound trough concentra-
tions among our patients were observed for the participant with
high creatinine clearance (2 mg/liter for P12) and those with
marked obesity (3 mg/liter for P10 and P11) (Table 1 and Fig. 2).
In such patients, extended infusion over half of the dosing interval
may significantly improve the probability of target attainment
without increasing the total dose administered, thus minimizing
the apparent toxicity concerns (15, 39). Clinical studies have re-
ported increased percentage of fTMIC with prolonged infusion
for cefepime (39, 40) and other-lactam antibiotics (15, 41). Cur-
rent PK/PD understanding is that improved exposure can poten-
tially translate into improved clinical outcome. In support of this,
a retrospective study by Bauer et al. (42) reported a mortality
benefit from the use of an extended-infusion cefepime regimen.
However, a recent systematic review by Burgess et al. (43) suggests
that, despite the accumulating evidence of improvedPK/PD target
attainment, the correlation of thiswith optimal clinical outcome is
yet to be demonstrated in awell-designed randomized prospective
study, given the methodological limitations of existing studies.
A similar limitation of this study is that no outcome assessment
was performed to describe if achievement of adequate PK/PD ex-
posure was associated with favorable patient outcomes. It was not
possible to perform any preliminary assessment because of the
small sample size and also the variability in the type and schedule
of concomitant antibiotic therapy (gentamicin for 1 to 3 days or
vancomycin). In addition, 4 out of 12 patients did not complete
cefepime therapy due to persisting fever. Even though this obser-
vation does not allow any conclusion (small sample size), a recent
study also reported clinical failure with cefepime therapy despite
achievement of 100% fTMIC (44). In addition to this, a previous
study has challenged the ability of existing cefepime breakpoints
to predict clinical outcomes (45). Taken altogether, there seems to
be accumulating evidence suggesting a need for critical reevalua-
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tion of PK/PD properties of cefepime to confirm if the current
dosing targets correlate with optimal clinical outcomes.
Conclusions. A high-dose cefepime regimen (2 g i.v. q8h) ap-
pears to provide appropriate antibiotic exposure in febrile neutro-
penic patients with normal renal function given that the MIC of
the anticipated organisms is4 mg/liter. However, based on cur-
rent PK/PD recommendations, it may frequently fail to achieve
maximum targets against higher MIC Gram-negative organisms.
Plasma drug concentrations are highly variable among patients,
suggesting that, in the absence of a well-defined therapeutic range
and common toxicity/treatment failure concerns, monitoring of
the cefepime concentration would be advantageous to support
rational clinical decisions. The correlation of current PK/PD rec-
ommendations with favorable patient outcomes deserves ongoing
thorough clinical investigation.
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